Ute Dugan
Impact in
- Modeling and Simulation top 10%
- Mathematical Biology Tumor Growth
-
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
Papers in
- Oncology 16
- Cancer Treatment and Pharmacology 9
- Colorectal Cancer Treatments and Studies 5
- Cancer Immunotherapy and Biomarkers 5
- HER2/EGFR in Cancer Research 4
- Pancreatic and Hepatic Oncology Research 3
- CAR-T cell therapy research 3
-
- Cancer Genomics and Diagnostics 3
- Co-authors
- Kenneth Kolinsky (6 shared papers)Larry Norton (6 shared papers)Clifford A. Hudis (5 shared papers)Maria Theodoulou (5 shared papers)Tiffany A. Traina (3 shared papers)David Heimbrook (4 shared papers)Kathryn Packman (4 shared papers)Brian Higgins (4 shared papers)
- Journals
- Journal of Clinical Oncology (5 papers)Cancer Research (3 papers)Molecular Cancer Therapeutics (1 paper)Clinical Trials (1 paper)Breast Disease (1 paper)
- Partner nations
- United StatesSouth AfricaEswatini
In The Last Decade
Ute Dugan
16 papers receiving 238 citations
Peers
Comparison fields: 5 of 46
- Modeling and Simulation 33
- Oncology 187
- Cancer Research 61
- Hepatology 25
- Immunology 47
Countries citing papers authored by Ute Dugan
This map shows the geographic impact of Ute Dugan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Dugan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Dugan more than expected).
Fields of papers citing papers by Ute Dugan
This network shows the impact of papers produced by Ute Dugan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Dugan. The network helps show where Ute Dugan may publish in the future.
Co-authors
The 25 scholars most cited alongside Ute Dugan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 55 | |
| 2 | 2008 | 52 | |
| 3 | 2009 | 34 | |
| 4 | 2010 | 27 | |
| 5 | Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. | 2007 | 21 |
| 6 | Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. | 2009 | 16 |
| 7 | 2019 | 13 | |
| 8 | 2021 | 8 | |
| 9 | 2008 | 6 | |
| 10 | 2009 | 5 | |
| 11 | 2007 | 5 | |
| 12 | 2007 | 2 | |
| 13 | 2023 | 1 | |
| 14 | 2024 | 1 | |
| 15 | 2021 | 1 | |
| 16 | 2007 | 1 | |
| 17 | 2025 | 0 |
About Ute Dugan
Ute Dugan is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Neurology and Hepatology, having authored 17 papers that have together received 248 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Genomics and Diagnostics (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), CAR-T cell therapy research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Modeling and Simulation (33 citations), Oncology (187 citations), Cancer Research (61 citations), Hepatology (25 citations) and Immunology (47 citations). Ute Dugan has collaborated with scholars based in United States, South Africa and Eswatini. Frequent co-authors include Kenneth Kolinsky, Larry Norton, Clifford A. Hudis, Maria Theodoulou, Tiffany A. Traina, David Heimbrook, Kathryn Packman, Brian Higgins, Kimberly Feigin and Sujata Patil. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Molecular Cancer Therapeutics, Clinical Trials and Breast Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.